1028 related articles for article (PubMed ID: 36546652)
1. Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease-Current Evidence.
Muzurović EM; Volčanšek Š; Tomšić KZ; Janež A; Mikhailidis DP; Rizzo M; Mantzoros CS
J Cardiovasc Pharmacol Ther; 2022; 27():10742484221146371. PubMed ID: 36546652
[TBL] [Abstract][Full Text] [Related]
2. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
Fisman EZ; Tenenbaum A
Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
[TBL] [Abstract][Full Text] [Related]
3. GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis.
Chen Y; Xu YN; Ye CY; Feng WB; Zhou QT; Yang DH; Wang MW
Acta Pharmacol Sin; 2022 May; 43(5):1156-1166. PubMed ID: 34934197
[TBL] [Abstract][Full Text] [Related]
4. Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor co-agonists for cardioprotection, type 2 diabetes and obesity: a review of mechanisms and clinical data.
Goldenberg RM; Teoh H; Verma S
Curr Opin Cardiol; 2023 Nov; 38(6):539-545. PubMed ID: 37792556
[TBL] [Abstract][Full Text] [Related]
5. The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease.
Andreasen CR; Andersen A; Vilsbøll T
Diabetologia; 2023 Oct; 66(10):1846-1858. PubMed ID: 37498367
[TBL] [Abstract][Full Text] [Related]
6. Potential role of tirzepatide towards Covid-19 infection in diabetic patients: a perspective approach.
Batiha GE; Al-Kuraishy HM; Al-Gareeb AI; Ashour NA; Negm WA
Inflammopharmacology; 2023 Aug; 31(4):1683-1693. PubMed ID: 37208555
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature.
Chrysavgis LG; Kazanas S; Bafa K; Rozani S; Koloutsou ME; Cholongitas E
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612640
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease.
Targher G; Mantovani A; Byrne CD
Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):179-191. PubMed ID: 36620987
[TBL] [Abstract][Full Text] [Related]
9. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
[TBL] [Abstract][Full Text] [Related]
10. OXM-104, a potential candidate for the treatment of obesity, NASH and type 2 diabetes.
Melander SA; Kayed A; Andreassen KV; Karsdal MA; Henriksen K
Eur J Pharmacol; 2024 Jan; 962():176215. PubMed ID: 38056618
[TBL] [Abstract][Full Text] [Related]
11. The role of incretin hormones and glucagon in patients with liver disease.
Junker AE
Dan Med J; 2017 May; 64(5):. PubMed ID: 28552096
[TBL] [Abstract][Full Text] [Related]
12. The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD.
Patel Chavez C; Cusi K; Kadiyala S
J Clin Endocrinol Metab; 2022 Jan; 107(1):29-38. PubMed ID: 34406410
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes.
De Block CEM; Dirinck E; Verhaegen A; Van Gaal LF
Diabetes Obes Metab; 2022 May; 24(5):788-805. PubMed ID: 34984793
[TBL] [Abstract][Full Text] [Related]
14. Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes.
Scheen AJ
Ann Endocrinol (Paris); 2023 Apr; 84(2):316-321. PubMed ID: 36639119
[TBL] [Abstract][Full Text] [Related]
15. [A new era for glucagon-like peptide-1 receptor agonists].
Neuville MF; Paquot N; Scheen AJ
Rev Med Liege; 2023 Jan; 78(1):40-45. PubMed ID: 36634066
[TBL] [Abstract][Full Text] [Related]
16. Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation.
Wang XC; Gusdon AM; Liu H; Qu S
World J Gastroenterol; 2014 Oct; 20(40):14821-30. PubMed ID: 25356042
[TBL] [Abstract][Full Text] [Related]
17. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
Skow MA; Bergmann NC; Knop FK
Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
[TBL] [Abstract][Full Text] [Related]
18. Incretin-based investigational therapies for the treatment of MASLD/MASH.
Brouwers B; Rao G; Tang Y; Rodríguez Á; Glass LC; Hartman ML
Diabetes Res Clin Pract; 2024 May; 211():111675. PubMed ID: 38636848
[TBL] [Abstract][Full Text] [Related]
19. The influence of Glucose-dependent Insulinotropic Polypeptide (GIP) on human adipose tissue and fat metabolism: Implications for obesity, type 2 diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD).
Thondam SK; Cuthbertson DJ; Wilding JPH
Peptides; 2020 Mar; 125():170208. PubMed ID: 31759125
[TBL] [Abstract][Full Text] [Related]
20. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity.
Gallwitz B
Front Endocrinol (Lausanne); 2022; 13():1004044. PubMed ID: 36313764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
